Article
Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
Cancer discovery - 1 Apr 2016
Elf Shannon, Abdelfattah Nouran S, Chen Edwin, Perales-Patón Javier, Rosen Emily A, Ko Amy, Peisker Fabian, Florescu Natalie, Giannini Silvia, Wolach Ofir, Morgan Elizabeth A, Tothova Zuzana, Losman Julie-Aurore, Schneider Rebekka K, Al-Shahrour Fatima, Mullally Ann
Abstract excerpt
UNLABELLED: Somatic mutations in calreticulin (CALR) are present in approximately 40% of patients with myeloproliferative neoplasms (MPN), but the mechanism by which mutant CALR is oncogenic remains unclear. Here, we demonstrate that expression of mutant CALR alone is sufficient to engender MPN in mice and recapitulates the disease phenotype of patients with CALR-mutant MPN. We further show that the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.